Department of Urology, Krankenhaus Rudolfstiftung, Vienna, Austria.
Department of Urology, Krankenhaus Mistelbach, Mistelbach, Austria,
Urol Int. 2021;105(3-4):264-268. doi: 10.1159/000511649. Epub 2020 Dec 17.
β-HCG has been the only tumor marker evaluated in testicular vein (VT) blood until now.
To evaluate the correlation between the tumor markers β-HCG, AFP, PLAP, and LDH from the VT and peripheral blood as well as their significance in predicting tumor recurrence and tumor stage.
Patients with testicular cancer undergoing orchiectomy were studied retrospectively over a period of 20 years. Tumor stage, tumor histology, time to tumor recurrence, and tumor markers from VT and peripheral blood were analyzed. Minimal follow-up was 2 years. Statistical analysis was performed by means of Cox- and logistic regression models and Spearman rank correlation coefficients.
A total of 172 patients with an average follow-up of 9.9 years were investigated. The overall recurrence rate was 18% (seminoma patients 20.8%, nonseminoma patients 14.5%). Marker values measured from VT blood were higher than in peripheral blood and correlated strongly with the peripherally measured values. AFP obtained from peripheral blood was the only tumor marker allowing a statement on the recurrence probability. Tumor markers from VT blood showed no correlation with tumor stage.
DISCUSSION/CONCLUSION: Tumor markers from VT blood are significantly higher than in peripheral blood. Tumor markers obtained from VT blood do not provide clinical advantage in terms of assessing tumor stage and recurrence probability.
到目前为止，β-HCG 一直是唯一在精索静脉（VT）血液中评估的肿瘤标志物。
评估 VT 和外周血中β-HCG、AFP、PLAP 和 LDH 肿瘤标志物的相关性及其在预测肿瘤复发和肿瘤分期中的意义。
回顾性研究了 20 年来接受睾丸切除术的睾丸癌患者。分析了肿瘤分期、肿瘤组织学、肿瘤复发时间以及 VT 和外周血中的肿瘤标志物。最小随访时间为 2 年。统计分析采用 Cox 和逻辑回归模型和 Spearman 秩相关系数。
共调查了 172 例平均随访 9.9 年的患者。总复发率为 18%（精原细胞瘤患者 20.8%，非精原细胞瘤患者 14.5%）。从 VT 血中测量的标志物值高于外周血，并且与外周测量值具有很强的相关性。从外周血获得的 AFP 是唯一可以说明复发概率的肿瘤标志物。从 VT 血中获得的肿瘤标志物与肿瘤分期无关。
讨论/结论：VT 血中的肿瘤标志物明显高于外周血。从 VT 血中获得的肿瘤标志物在评估肿瘤分期和复发概率方面没有提供临床优势。
